Covaxin receives GMP certificate from Hungary, says Bharat Biotech

Bharat Biotech's Covid-19 vaccine Covaxin has received Good Manufacturing Practices (GMP) compliance certificate from Hungary, the vaccine maker said on Thursday in a tweet

Bharat Biotech, Covaxin
Photo: Shutterstock
Press Trust of India Hyderabad
1 min read Last Updated : Aug 05 2021 | 11:07 AM IST

: Bharat Biotech's COVID-19

vaccine Covaxin has received Good Manufacturing Practices (GMP) compliance certificate from Hungary, the vaccine maker said on Thursday in a tweet.

"Another milestone in our account as COVAXIN receives GMP certificate from Hungary. This marks the 1st EUDRAGDMP compliance certificate received by Bharat Biotech from European regulatories," the tweet said.

The approval received is from the National Institute of Pharmacy and Nutrition, Hungary certifying the GMP for the manufacture of Covaxin, a note posted on twitter said.

The certificate of GMP is now listed on the EudraGMDP database which is the collection of records of the European Community of manufacturing authorisations and certificates of good manufacturing practice, Bharat Biotech said.

Bharat Biotech intends to submit documentation for emergency use authorisation to several additional countries worldwide, the company said.

"With this approval Bharat Biotech has achieved another significant milestone in innovating and manufacturing vaccines at Global quality standards and moving forward in the ongoing fight against the COVID-19 pandemic," the note said.

The recognition compliments the firm's commitment of driving world class innovation and being a frontrunner in the research and development of vaccines, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Bharat BiotechCoronavirus VaccineHungary

First Published: Aug 05 2021 | 11:07 AM IST

Next Story